zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2024 / Oneness announce re-election of all directors in the 2024 Annual General Shareholders’ Meeting.

Oneness announce re-election of all directors in the 2024 Annual General Shareholders’ Meeting.

2024-05-21

Published Date:2024-05-21

Original Link:https://www.onenessbio.com/en/news_detail290_3.htm

No 2 Date of announcement 2024/05/21 Time of announcement 17:41:48
Subject Oneness announce re-election of all directors in the 2024 Annual General Shareholders’ Meeting.
To which item it meets paragraph 6 Date of events 2024/05/21
Statement
  1. Date of occurrence of the change: 2024/05/21
  2. Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): independent director, natural-person director
  3. Title and name of the previous position holder:
    1. (1)Director: Huang, Shan-Ney
    2. (2)Director: Lin, Yi-Fu
    3. (3)Director: Microbio Co., Ltd. Representative: Hsu, Shih-Hua
    4. (4)Independent director: Huang, San-Kuei
    5. (5)Independent director: Wu, Rey-Yuh
    6. (6)Independent director: Lu, Suei
    7. (7)Independent director: Huang, Jui-Wen
  4. Resume of the previous position holder:
    1. (1)Director: Huang, Shan-Ney/Chairman of Oneness biotech Co., Ltd.
    2. (2)Director: Lin, Yi-Fu/Minister of Economic Affairs
    3. (3)Director: Hsu, Shih-Hua/Representative Director of Oneness biotech Co.,Ltd.
    4. (4)Independent director: Huang, San-Kuei/Director of General, National Health Insurance Administration, Ministry of Health and Welfare
    5. (5)Independent director: Wu, Rey-Yuh/Team Leader of Development Center for Biotechnology
    6. (6)Independent director: Lu, Suei/Assistant Vice President of Management Department of Microbio Co., Ltd.
    7. (7)Independent director: Huang, Jui-Wen/Financial deputy general manager of 3D Global Biotech Inc.
  5. Title and name of the new position holder:
    1. (1)Director: Kuo, Hsien-Shou
    2. (2)Director: Kuo, Tu-Mu
    3. (3)Director: Lin, Yi-Fu
    4. (4)Independent director: Huang, San-Kuei
    5. (5)Independent director: Wu, Rey-Yuh
    6. (6)Independent director: Lu, Suei
    7. (7)Independent director: Huang, Jui-Wen
  6. Resume of the new position holder:
    1. (1)Director: Kuo, Hsien-Shou/Chairman and President of Microbio Co., Ltd.
    2. (2)Director: Kuo, Tu-Mu/Representative Director of DIAMOND BIOFUND INC.
    3. (3)Director: Lin, Yi-Fu/Minister of Economic Affairs
    4. (4)Independent director: Huang, San-Kuei/Director of General, National Health Insurance Administration, Ministry of Health and Welfare
    5. (5)Independent director: Wu, Rey-Yuh/Team Leader of Development Center for Biotechnology
    6. (6)Independent director: Lu, Suei/Assistant Vice President of Management Department of Microbio Co., Ltd.
    7. (7)Independent director: Huang, Jui-Wen/Financial deputy general manager of 3D Global Biotech Inc.
  7. Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”): Term expired
  8. Reason for the change: Re-election of all directors
  9. Number of shares held by the new position holder when elected:
    (1)Kuo, Hsien-Shou 11,000 Shares
    (2)Kuo, Tu-Mu 0 Share
    (3)Lin, Yi-Fu 0 Share
    (4)Huang, San-Kuei 0 Share
    (5)Wu, Rey-Yuh 0 Share
    (6)Lu, Suei 0 Share
    (7)Huang, Jui-Wen 0 Share
  10. Original term (from __________ to __________): 2021/08/18~2024/08/17
  11. Effective date of the new appointment: 2024/05/21
  12. Turnover rate of directors of the same term: Re-election of all directors; NA.
  13. Turnover rate of independent directors of the same term: Re-election of all directors; NA.
  14. Turnover rate of supervisors of the same term: NA.
  15. Change in one-third or more of directors (Please enter “Yes” or “No”): No.
  16. Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 6 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): None.